Masatomo Otsuka

发表

Additive Duloxetine for Cancer-related Neuropathic Pain Nonresponsive or Intolerant to Opioid-Pregabalin Therapy: A Randomized Controlled Trial (JORTC-PAL08).

H. Sakuma, Y. Matsuda, H. Matsuoka, 2019, Journal of pain and symptom management.

Predictors of duloxetine response in patients with neuropathic cancer pain: a secondary analysis of a randomized controlled trial—JORTC-PAL08 (DIRECT) study

H. Sakuma, Y. Matsuda, H. Matsuoka, 2019, Supportive Care in Cancer.

Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients.

T. Yamanaka, K. Nishio, Y. Tanigawara, 2012, Oncology reports.

Incidence of carnitine deficiency in patients with cancer pain: A pilot study

K. Nishio, H. Matsuoka, Masatomo Otsuka, 2017, Molecular and clinical oncology.

Early palliative intervention for patients with advanced cancer.

M. Fukuoka, H. Matsuoka, Masatomo Otsuka, 2013, Japanese journal of clinical oncology.

Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients.

T. Yamanaka, K. Nishio, H. Matsuoka, 2011, Anticancer research.

Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin.

H. Matsuoka, Masatomo Otsuka, A. Koyama, 2012, Anticancer research.

Chemotherapeutic drugs that penetrate the blood–brain barrier affect the development of hyperactive delirium in cancer patients

H. Matsuoka, Masatomo Otsuka, A. Koyama, 2014, Palliative and Supportive Care.

Factors Associated with Length of Stay at Home in the Final Month of Life among Advanced Cancer Patients: A Retrospective Chart Review.

Masatomo Otsuka, 2017, Journal of palliative medicine.

〈Originals〉The significance of a specific psycho-oncology outpatient service for cancer patients run by psychosomatic medical doctors

H. Matsuoka, Masatomo Otsuka, K. Sakai, 2011 .